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Abstract
Introduction: Urinary stone disease is a common urologic problem and recurrence in stone formation is a 
very familiar issue to urologists. Although recurrence in stone formation has been linked to metabolic abnor-
malities, it can be accessible by metabolic risk analysis studies. 
Methods: Herein, we present our experience in metabolic risk management on recurrence of urinary stones 
for 10 years in Akdeniz University School of Medicine department of Urology. We retrospectively analyzed 
Akdeniz University Urinary Stone Database between dates of January 2000 and December 2010. We found 
over 3500 patients who were managed by SWL (shock wave lithotripsy) or PCNL (percutaneus nephrolitho-
tripsy) or URS (Ureterorenoscopic lithotripsy) or open surgery. 
Results: 525 patients’ metabolic risk analysis was ordered due to recurrent urinary stone disease. Only 134 
(25.5 %) current metabolic analysis were returned. Mean patient age was 32.2 years (range: 19-82 years). 
Patients were 103 male and 31 female. Stone analysis results were CaOx monohydrate in 48 (35.8 %), CaOx 
dihydrate in 8 (5.9 %), CaOx mono and dihydrate in 70 (52.2 %), uric acid in 3, CaOx monohydrate and uric 
acid in 2, cystine in 2, and struvite in 1 patient, respectively. The metabolic risk analysis showed some abnor-
mality in 54 (40.2 %) patients. 
Conclusion: Although compliance to metabolic risk analysis studies is low among recurrent urinary stone 
formers, some significant metabolic abnormalities could be detected in those who are effectively screened. 
Recurrence of urinary stones in patients who are started on appropriate metabolic management can be pre-
vented. © 2012 All rights reserved
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Introduction
Urinary stone disease is a common urologic prob-
lem and recurrence in stone formation is a very 
familiar issue to urologists. Distinct genetic, con-
genital, metabolic, and nutritional mechanisms 
have been found to underlie this common dis-
order and account for the wide variation in the 
geographical prevalence and stone patterns in dif-
ferent populations (1). Epidemiologically, urinary 
stone disease is more common in males (male/
female = 3/1), hot climatic zone, fair-skinned 
people,, people with metabolic disorders (primary 
hypocitraturia, primary hyperoxaluria, cystinuria, 
xantinuria), dietary habits (nutrition of mainly 
protein, carbonhydrate or oxalate) (2, 3). 15 % 
of the population will develop urinary stone dis-
ease over life time (4). Daily life in a western af-
fluent society provides a bundle of factors which 
impair urine composition and thereby increase 
the stone formation risk: generally people do 
not drink enough and only twice or thrice a day, 
they eat food that is too rich in calories and ta-
ble salt, but have deficiencies in fiber and alkali. 
Despite the highly developed health care systems 
in the western world, the stone disease itself seems 
to be an unresolved issue (5). Diagnostic tools 
(especially the high availability of ultrasound and 
computerized tomography-scans in routine prac-
tice) allow today the diagnosis of clinically dumb 
urinary calculi. Although, it is important to diag-
nose and treat urinary stone disease, prevention of 
recurrence is very important (6). Metabolic evalu-
ations have allowed the identification of physi-
ological or environmental causes of urinary cal-
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culi in more than 97 % of patients (7). Although 
recurrence in stone formation has been linked 
to metabolic abnormalities which can be acces-
sible by metabolic risk analysis studies, only few 
data is present proving the management of meta-
bolic risks may effectively decrease the recurrence. 
In this retrospective study, we analyzed our 10-
year urinary stone database to search the effect of 
metabolic management of risk factors detected by 
risk analysis studies on recurrent stone formers.
Methods 
Patients
We retrospectively analyzed Akdeniz Univer-
sity Urinary Stone Database between dates of 
January 2000 and December 2010. We found 
over 3500 patients who were managed by SWL 
(shock wave lithotripsy) or PCNL (percutane-
ous nephrolithotomy) or URS (Ureteroreno-
scopic lithotripsy) or open surgery. All patients 
were recorded according to their age, sex, previ-
ous urinary stone disease, previous and current 
stone analysis, previous and current metabolic 
analysis, previous and current metabolic manage-
ment, current stone burden, current stone loca-
tion, modality of intervention, results of interven-
tion and current stone status on the last visit date.
Management of urinary stones 
We have been using “Siemens lithostar” for SWL 
(stones in kidney, ureter or bladder) standard 
PCNL techniques (for kidney stones), semirigid or 
flexible ureterorenoscopy (for stones in ureter and 
kidney), and classic open surgery procedures in 
urinary stones (pyelolithotomy, nephrolithotomy, 
uretherolithotomy, open surgical procedures for 
bladder stones) (8-10). We used pneumatic litho-
tripter or ND –YAG laser for endoscopic procedures.
Urine and metabolic analysis
Subjects were given an order for a metabolic 
stone evaluation to be performed at home. Two 
24-hour urine collections were collected at home 
and brought to our central laboratory. The evalu-
ation included standard urinary indexes, such as 
volume, level of creatinine, magnesium, phos-
phate, albumin, calcium, oxalate, citrate, uric 
acid and pH, as well as urinary calcium oxalate, 
calciumphosphate and uric acid supersaturation. 
Urine chemistry studies, such as calcium, citrate, 
uric acid and oxalate, were adjusted for urine cre-
atinine. Urine pH, calcium oxalate, calciumphos-
phate and uric acid supersaturation were assessed 
but did not require correction using creatinine ex-
cretion. As well as urinary analysis, blood analysis 
was performed to urinary stone disease patients. 
We analyzed levels of sodium, calcium, potassium, 
parathormone, albumin, magnesium, phosphate, 
creatinine, and blood urea nitrogen in the blood.
Stone analysis
We gave a urinary stone analysis form of MTA 
(Maden tetkik arama enstitüsü – govermental 
mineral etude institute) to all urinary stone dis-
ease patients after they reduced urinary stone or 
after PCNL or URS operation. Patients have post-
ed MTA form and as least 3 cm3 stone burden to 
MTA research laboratory. Urinary stones analyzed 
with electrospectracally (X-ray defraction meth-
ods) in MTA, according to its quality and quantity. 
Statistical analysis
Descriptive statistical methods were used.
Results 
525 patients’ metabolic risk analysis was ordered 
due to recurrent urinary stone disease. Only 134 
(25.5 %) current metabolic analysis were returned. 
Mean patient age was 32.2 years (range: 19-82 
years). Patients were 103 male and 31 female. 
PCNL procedure was used for 92 (68 %) patients, 
URS was used for 7 patients (6 %), and SWL was 
used for 35 patients (26 %). Stone analysis results 
were CaOx monohydrate in 48 (35.8 %), CaOx di-
hydrate in 8 (5.9 %), CaOx mono and dihydrate 
in 70 (52.2 %), uric acid in 3, CaOx monohydrate 
and uric acid in 2, cystine in 2, and struvite in 1 
patient, respectively. The metabolic risk analysis 
showed some abnormality in 54 (40.2 %) patients. 
The most common abnormality was hypocitratu-
ria in 31 (57.4 %) patients. The second and third 
most common abnormalities were hyperoxaluria 
in 21 (38.8 %) and hypercalciuria in 19 (35.1 %) 
patients, respectively (Table 1). No primary hyp-
eroxaluria was noted. In 2 hypercalciuric patients 
primary hyperparathyroidism was found and re-
ferred to adenoma removal. In other 2 hypercalci-
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uric cases renal type hypercalciuria was found and 
started on thiazide diuretics. Patients were started 
on metabolic management by urinary alkaliza-
tion, citrate replacement, Vit B6 replacement, al-
lopurinol and dietary restrictions accordingly. 
All patients were followed up for a mean of 16 
months (range: 2-9 years) with renal ultrasound 
and KUB (Kidney ureter and bladder x-ray). In 
8 (5.9 %) patients, stone recurrence was detected. 
Recurrent stone formers demonstrated stone types 
as CaOx monohydrate in 5, cystine in 1, uric acid 
in 1, CaOx dihydrate and uric acid in 1 patient, re-
spectively. Their metabolic abnormalities were hy-
percalciuria in 3 (1 rejected parathyroid adenoma 
removal and 1 stopped thiazides), hyperoxaluria in 
1, hypocitraturia and hyperoxaluria in 1, and hy-
peruricosuria in 1 (stopped allopurinol treatment) 
patient, respectively (Table 1). Remaining one re-
currence was in a cystinuric case while the other 
recurrence showed no metabolic abnormality. 
Discussion
The diverse manifestations of urolithiasis provide 
a very interesting epidemiological study from the 
standpoints of geography, socioeconomic status, 
nutrition and culture, which ultimately affect the 
stone structure and composition (11). The past 100 
years have produced revolutionary changes in the 
anatomical and clinical pathology of stone disease 
in the whole World (12). Improved technology 
has revolutionized the management of stones: the 
advent of SWL, fiber-optic, semi-rigid and flexible 
ureteroscopes, and narrow-caliber endoscopes, 
and minimally invasive options in addition to pre-
vailing open surgical procedures have expanded. 
The basic idea is to select the best possible modality 
to make the treatment better controlled. Addition-
ally, to keep in mind the morbidity and cost-effec-
tiveness of the procedure in today’s context. After 
treatment of urinary stone, it is very important to 
inform patients about the recurrence of urinary 
stones. Medical treatment, metaflaxi and modifi-
cations in dietary habits can help to prevent recur-
rence of urinary stones. Medical treatment should 
be based on assessing 24h urinary metabolic ab-
normalities (13). Drug treatment is advised after 
a high fluid intake (>3 L/day). Dietary modifica-
tions in the long term fail to correct abnormalities 
or prevent recurrence. Available trials offer urolo-
gists excellent treatment strategies for prevention 
of calcium stones. Since uric acid stones are a 
consequence of low urine pH, urologists can treat 
them confidently despite the lack of prospective 
trials for additional therapeutics. Although with 
imperfect treatment, the cystine stones could also 
be prevented. Although potassium citrate salts 
are effective along with ESWL, they may promote 
the formation of calcium phosphate stones, the 
prevalence of which continues to rise with time. 
Abnormal urine pH and calcium excretion rate 
are predominant findings that play a major role in 
the pathogenesis of stone formation (14). Recent 
evidence strongly supports the concept that di-
etary calcium restriction does not protect against 
calcium stone formation and that a reduced cal-
cium diet is detrimental, leading to bone loss, in 
hypercalciurias other than absorptive type I (15). 
In fact, it appears that urinary calcium excretion 
in most renal stone formers is more dependent on 
the dietary acid load than on the dietary calcium 
intake itself (16). The excess acid load in a diet rich 
in animal protein is mainly buffered by the bone, 
leading to calcium resorption and consequently 



























































































































Patient number: 54 16 8 7 7 6 4 2 2 1 1
Patient numbers of recur-
rent urinary stones 
Patient number: 6
1 3 1 1
Table 1.  Patient and stone disturbition.
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acid load either by dietary modifications or alkali 
therapy has an impact on decreasing stone recur-
rence, while preventing bone loss. New evidence 
associates the decolonization of oxalate degrading 
intestinal flora with a higher risk of calcium oxa-
late stone formation, possibly opening the door 
for biological manipulation as a novel approach 
for the prevention of urinary stone formation.
We must not leave the stones unturned. Roughly 
25 % of the stone formers belong to the high risk 
group and definitively need specific measures to 
prevent frequent stone recurrences. Patients form-
ing “civilization stones” or suffering from the met-
abolic syndrome, respectively, benefit from the 
recommended measures of metaphylaxis in a mul-
tifold way. As far as children are concerned, keep 
in mind that most of the stones formed in child-
hood have a metabolic basis and hence, early di-
agnosis is mandatory for the purpose of adequate 
treatment (18). It is the best to treat the “cause” 
of disease instead of removing its “symptom”. 
Conclusion
Although compliance to metabolic risk analy-
sis studies is low among recurrent urinary stone 
formers, some significant metabolic abnormali-
ties could be detected in those who are effec-
tively screened. Recurrence of urinary stones in 
patients who are started on appropriate meta-
bolic management can be prevented. Patients 
should be warned about the close relationship 
between metabolic risk screening and compli-
ance to management and urinary stone recurrence.
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